Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its Phase 2 trial of Zybrestat, a potential treatment for patients with polypoidal choroidal vasculopathy, a degenerative eye disease with features similar to age-related macular degeneration. The data was presented today at the annual meeting of the American Academy of Ophthalmology.
Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs